A biotech company focusing on Selective Estrogen Receptor Degraders (CERDs) for breast cancer.
Investment Insights
AI-generated insights about Olema Pharmaceuticals from various financial sources
Thursday, November 20, 2025
The host is short the stock based on fundamental skepticism, noting its drug would be 'fifth or sixth' to market. Believes it could fade back to the $22 level despite strong recent buying pressure.
Wednesday, November 19, 2025
The speaker is actively shorting the stock, believing a recent rally was an unsustainable 'weird squeeze' and expects the price to decline.
Tuesday, November 18, 2025
The speaker is actively shorting the stock, calling it 'dog poo poo' and believes it is in a very crowded and competitive market. They see a potential price target of $12 for the day.
Thursday, November 20, 2025
The host is short the stock based on fundamental skepticism, noting its drug would be 'fifth or sixth' to market. Believes it could fade back to the $22 level despite strong recent buying pressure.
Wednesday, November 19, 2025
The speaker is actively shorting the stock, believing a recent rally was an unsustainable 'weird squeeze' and expects the price to decline.
Tuesday, November 18, 2025
The speaker is actively shorting the stock, calling it 'dog poo poo' and believes it is in a very crowded and competitive market. They see a potential price target of $12 for the day.